4.13
-0.0357(-0.86%)
Currency In USD
| Previous Close | 4.17 |
| Open | 4.15 |
| Day High | 4.28 |
| Day Low | 4.13 |
| 52-Week High | 5.91 |
| 52-Week Low | 3.36 |
| Volume | 3,535 |
| Average Volume | 5,893 |
| Market Cap | 154.44M |
| PE | -2.03 |
| EPS | -2.03 |
| Moving Average 50 Days | 4.23 |
| Moving Average 200 Days | 3.89 |
| Change | -0.04 |
If you invested $1000 in Molecular Partners AG (MOLN) since IPO date, it would be worth $210.18 as of January 14, 2026 at a share price of $4.13. Whereas If you bought $1000 worth of Molecular Partners AG (MOLN) shares 3 years ago, it would be worth $590 as of January 14, 2026 at a share price of $4.13.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Molecular Partners Highlights Clinical Development Progress and Anticipated Milestones at 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 11, 2026 8:00 PM GMT
Phase 1/2a study with lead Radio-DARPin MP0712 initiated; first patient dosing expected Q1 2026, initial data anticipated in 2026Full imaging and dosimetry data from MP0712 compassionate care program to be presented at TWC 2026Phase 2 investigator-in
Molecular Partners to Present at 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Dec 18, 2025 6:00 AM GMT
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics
Molecular Partners Forms Scientific Advisory Board to Accelerate Development of Targeted Radiotherapeutics
GlobeNewswire Inc.
Dec 11, 2025 12:00 PM GMT
Chaired by globally renowned nuclear medicine expert Prof. Ken Herrmann, M.D. Other Board members James Cook, Jason Lewis, Ph.D., and Michael Morris, M.D. bring significant clinical and industry expertise, supporting transition from early clinical va